Xenetic Biosciences Q2 EPS $(0.83) Misses $(0.15) Estimate, Sales $726.40K Beat $570.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Xenetic Biosciences (NASDAQ: XBIO) reported Q2 EPS of $(0.83), missing the $(0.15) estimate by a significant margin. However, sales of $726.40K beat the $570.00K estimate.
August 14, 2024 | 1:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Xenetic Biosciences reported a significant EPS miss but exceeded sales expectations. The mixed results may lead to short-term volatility in the stock price.
The significant EPS miss indicates higher-than-expected losses, which is negative. However, the sales beat shows positive revenue growth. These mixed signals could result in short-term volatility as investors digest the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100